Read by QxMD icon Read

Clostridium histolyticum

Keisuke Tanaka, Naoko Teramura, Osamu Hayashida, Katsumasa Iijima, Teru Okitsu, Shunji Hattori
The collagenase secreted by Grimontia hollisae strain 1706B is a 74 kDa protein that consists of two parts: the catalytic module and a C-terminal segment that includes the bacterial pre-peptidase C-terminal domain. Here, we produced a recombinant C-terminal segment protein and examined its ability to bind collagen and other characteristics as compared with collagen-binding domains (CBDs) derived from Hathewaya histolytica ( Clostridium histolyticum ) collagenases; these CBDs are the only ones thus far identified in bacterial collagenases...
October 2018: FEBS Open Bio
Raanan Tal
No abstract text is available yet for this article.
October 17, 2018: International Journal of Impotence Research
Werner Girsch, Rohit Arora, Eva-Maria Baur, Markus Gabl, Dietmar Hager, Thomas Hintringer, Lars-Peter Kamolz, Rupert Koller, Christian Krasny, Martin Leixnering, Walpurga Lick-Schiffer, Matthias Rab, Ingrid Schlenz, Gottfried Wechselberger, Gerlinde Weigel, Armin Zadra, Robert Zimmermann
Dupuytren's contracture (DC) or Dupuytren's disease (DD) is a progressive fibro-proliferative disease of palmoplantar connective tissue, resulting in characteristic nodal and/or cord formation from collagen disposition. When the disease progresses, the thickening and shortening of the cords eventually leads the affected fingers to being pulled into flexion, which may be associated with marked disability, especially with bilateral disease. DD is relatively common in Europe, with the highest prevalence in Nordic countries...
October 17, 2018: Handchirurgie, Mikrochirurgie, Plastische Chirurgie
Andrew K Sefton, Belinda J Smith, David A Stewart
BACKGROUND: Dupuytren's disease results in contracted cords in the hand that lead to deformity and disability. Current treatment options include fasciectomy and an injectable, collagenase clostridium histolyticum. No cost comparison studies have been published within the Australian health care environment. METHODS: A retrospective review of all patients treated for Dupuytren's disease in a major teaching hospital was undertaken to compare the costs of treatment by fasciectomy or collagenase injection...
September 2018: Journal of Hand Surgery Asian-Pacific Volume
Takako Kanatani, Issei Nagura, Yoshifumi Harada
We describe our injection method for Collagenase Clostridium Histolyticum using a medical silicone tube after determining the optimal depth by ultrasonography. This procedure adjusts the exposed needle length to the planned injection depth by placing a sterilized silicone tube over the needle. The restricted depth provides not only precise injection into the middle of the cords but also avoids needle tip migration through the cord and into the vital structures, which prevents possible complications. This method is safe and simple...
September 2018: Journal of Hand Surgery Asian-Pacific Volume
Faysal A Yafi
No abstract text is available yet for this article.
September 28, 2018: International Journal of Impotence Research
Franck M Leclère, Sabine Kohl, Cédric Varonier, Frank Unglaub, Esther Vögelin
INTRODUCTION: In Switzerland, collagenase Clostridium histolyticum therapy (CCH) for Dupuytren's disease was introduced in 2011. This study analyzes possible differences between CCH and limited fasciectomy (LF) in terms of range of motion, patient satisfaction and postoperative rehabilitation. MATERIALS AND METHODS: This retrospective study included 52 patients with Dupuytren's disease stage 1-3 according to Tubiana, treated with CCH or LF between January 2012 and December 2013...
September 26, 2018: Archives of Orthopaedic and Trauma Surgery
Rafael Sanjuan-Cerveró, Francisco J Carrera-Hueso, Pedro Vazquez-Ferreiro
BACKGROUND: Collagenase clostridium histolyticum is now recognized as a viable treatment for Dupuytren disease. The high rate of adverse effects reported in patients continues to spark debate and raise questions about the true frequency of effects and their associated mechanisms of action. HYPOTHESIS: To investigate whether outcomes of CCH treatment are related to the number of adverse effects experienced. To evaluate short-term clinical outcomes in a series of patients...
October 2018: Orthopaedics & Traumatology, Surgery & Research: OTSR
J Kaminetsky, M Gittelman, G J Kaufman, T M Smith, G H Jordan
Intralesional injection of collagenase clostridium histolyticum (CCH) improves Peyronie's disease (PD) symptoms; however, patient perspectives regarding PD and CCH treatment have not been fully elucidated. This cross-sectional qualitative study included heterosexual men with PD who received ≥1 injection of study medication and had ≥1 posttreatment Peyronie's Disease Questionnaire (PDQ) assessment during a prior phase 2b clinical trial. These patients were "responders" if they reported (as part of the Global Assessment of the PDQ) that overall symptoms and effects of PD had at least "improved in a small but important way" after CCH therapy...
September 20, 2018: International Journal of Impotence Research
Giorgio Ivan Russo, Uros Milenkovic, Wayne Hellstrom, Laurence A Levine, David Ralph, Maarten Albersen
CONTEXT: Conservative therapies for Peyronie's disease (PD) aim to treat early-stage disease by improving clinical outcomes such as penile curvature, penile length erectile dysfunction, and pain. OBJECTIVE: To summarise the available evidence regarding injection and mechanical therapies for PD treatment. EVIDENCE ACQUISITION: An extensive search of Medline, Embase, and Scopus databases retrieved English-language articles up to 15 May 2018...
September 17, 2018: European Urology
David Shin, Tejash Shah, Hossein Sadeghi-Nejad
Xiaflex or collagenase Clostridium histolyticum intralesional injections are safe and effective as first-line treatment for Peyronie's disease.
September 10, 2018: European Urology Focus
E Soreide, M H Murad, J M Denbeigh, E A Lewallen, A Dudakovic, L Nordsletten, A J van Wijnen, S Kakar
Aims: Dupuytren's contracture is a benign, myoproliferative condition affecting the palmar fascia that results in progressive contractures of the fingers. Despite increased knowledge of the cellular and connective tissue changes involved, neither a cure nor an optimum form of treatment exists. The aim of this systematic review was to summarize the best available evidence on the management of this condition. Materials and Methods: A comprehensive database search for randomized controlled trials (RCTs) was performed until August 2017...
September 2018: Bone & Joint Journal
Juan Rodolfo Mella, Lifei Guo, Virginia Hung
Dupuytren's contracture, a benign condition characterized by fibrosis of the palmar and digital fascia, may be a debilitating condition that limits daily function. Several techniques exist for managing symptomatic contractures of the hand related to Dupuytren's. These techniques include the more invasive open fasciotomy or fasciectomy. More recently, less invasive techniques including administration of collagenase Clostridium histolyticum (CCH) or percutaneous needle aponeurotomy (PNA) have become part of the treatment armamentarium...
August 29, 2018: Annals of Plastic Surgery
Timothy T Fei, Evan Chernoff, Nathan A Monacco, David E Komatsu, Samantha Muhlrad, Steven P Sampson, Lawrence C Hurst, Alexander B Dagum
PURPOSE: To explore the efficacy of injectable collagenase Clostridium histolyticum (CCH) in distal interphalangeal (DIP) joint contractures in Dupuytren disease. METHODS: A retrospective review was conducted for patients with DIP joint contractures treated with CCH. Baseline contracture and posttreatment residual contracture were recorded. The primary end point was achievement of 0° to 5° of residual contracture 30 days postmanipulation. Recurrence and adverse events are also reported...
August 23, 2018: Journal of Hand Surgery
Peter N Tsambarlis, Raymond Yong, Laurence A Levine
Collagenase clostridium histolyticum (CCH) was approved for the treatment of Peyronie's disease (PD) in December of 2013. Recently, further research has supported its use. The aim of this study was to objectively evaluate the effects of CCH on penile curvature associated with Peyronie's disease at our high volume institution. Since the approval of CCH for PD, 45 men have undergone between 1 and 4 treatment cycles (mean 3.13, standard deviation (SD) = 0.87) at our institution. Primary as well as secondary curvature, if any, was measured before beginning therapy and after each cycle of therapy...
August 17, 2018: International Journal of Impotence Research
Jens C Werlinrud, Karina L Hansen, Søren Larsen, Jens Lauritsen
This study assesses the joint-specific sustained effect of collagenase clostridium histolyticum treatment of Dupuytren disease over a 5-year follow-up period. The study includes 107 consecutive treatments in patients with extension deficits greater than 20° affecting the metacarpophalangeal or proximal interphalangeal joints. Success was defined as no follow-up treatment due to relapse or maintained extension deficit less than 20°. The 5-year estimate of no follow-up treatment was 79% (95% CI: 64-88) for metacarpophalangeal and 49% (95% CI: 26-69) for proximal interphalangeal joints, which was a significant difference (log-rank test, p = 0...
October 2018: Journal of Hand Surgery, European Volume
Faysal A Yafi, Linley Diao, Kenneth J DeLay, Ling DeYoung, Riad Talib, Laith Alzweri, Gerald Brock, Wayne J G Hellstrom, Georgios Hatzichristodoulou
OBJECTIVE: To compare in a prospective, non-randomized fashion the outcomes of Collagenase Clostridium Histolyticum (CCH) and surgical interventions (tunical plication [TP] and partial plaque excision and grafting [PEG]) in patients with PD. Intralesional injection of CCH is the only Food and Drug Administration-approved non-surgical intervention for Peyronie's disease (PD). MATERIALS AND METHODS: Between 6/2015 and 1/2017, 57 patients with PD and dorsal, dorsolateral and/or lateral penile curvatures 30-90 degrees were included in this study...
July 27, 2018: Urology
Gary M Pess, Maj Sundbom, Koo Wilson, Daniel Lindqvist, Lars B Dahlin
This post hoc analysis from a multicenter study (NCT01674634) was designed to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) treatment in patients with different stages of Dupuytren contracture. Previously untreated patients who received two concurrent injections of CCH in two affected joints in the same finger were assessed by disease severity (Tubiana stage). The mean (SD) improvement in total fixed flexion contraction (FFC) 31 days post-CCH treatment in 181 patients was: 71.1 (36.5)% for Tubiana I, 77...
July 24, 2018: Journal of Plastic Surgery and Hand Surgery
Perry Caviness, Ryan Bauer, Keisuke Tanaka, Katarzyna Janowska, Jeffrey Randall Roeser, Dawn Harter, Jes Sanders, Christopher Ruth, Osamu Matsushita, Joshua Sakon
To penetrate host tissues, histotoxic clostridia secrete virulence factors including enzymes to hydrolyze extracellular matrix. Clostridium histolyticum, recently renamed as Hathewaya histolytica, produces two classes of collagenase (ColG and ColH). The high-speed AFM study showed that ColG collagenase moves unidirectionally to plane collagen fibril and rebundles fibril when stalled . The structural explanation of the roles for the tandem collagen-binding segment (CBDs) is illuminated by its calcium-bound crystal structure at 1...
September 2018: FEBS Journal
Marie A Badalamente, Lawrence C Hurst
Proof-of-principle, basic-science studies, using a rat-tail tendon model and surgically removed Dupuytren cords, began collagenase Clostridium histolyticum (CCH) development. Clinical studies in humans were then conducted, where the primary endpoint was reduction in contracture to within 0° to 5° of extension. Phase 2 studies, which confirmed the optimal dose of collagenase as 0.58 mg, showed injectable CCH reduced contractures in MP and PIP joints to within 0° to 5° in many joints and was well tolerated...
August 2018: Hand Clinics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"